Celularity Announces Phase 1 Data Showing That MLASC Therapy in Patients With Crohn’s…
<!-- Name:DistributionId Value:8843168 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
Celularity
Celularity Completes Strategic Review of 2023 Initiatives, Including Anticipated…
Commercial Biomaterials Business, Degenerative Disease Programs Continue to Gather Momentum Animal and Preclinical Data Support Significant Opportunities in Osteoarthritis for…
Celularity’s Placental-Derived Allogeneic Cell Therapy Provides Clinically Meaningful…
Legacy studies employing a single treatment course of two infusions seven days apart demonstrated greatest benefit in three early studies Data support further investigation of novel…
Imugene’s onCARlytics combination with Celularity’s placental-derived off-the-shelf…
SYDNEY, Australia and FLORHAM PARK, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company and Celularity Inc. (Nasdaq: CELU)…
Celularity Publishes New Data in Frontiers in Immunology Demonstrating…
FLORHAM PARK, N.J., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (Celularity), a clinical-stage biotechnology company developing placental-derived allogeneic cell…
Celularity Receives Orphan Drug Designation from U.S. FDA for its NK Cell Therapy…
CYNK-101 is an investigational genetically modified NK cell therapy designed to synergize with antibody therapeutics for difficult to treat cancers of high unmet medical need Phase 1/2a…
Celularity Receives Fast Track Designation from U.S. FDA for its NK Cell Therapy…
FLORHAM PARK, N.J., Dec. 27, 2021 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived allogeneic cell…